ELAN — Elanco Animal Health Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1739104 ·
Last close
$24.50
Market Cap
$12.24B
52W High
$26.29
52W Low
$19.40
ADV30
6,919,971
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,371,000,000 | 785,000,000 | 169,000,000 | 57,000,000 | 13,222,000,000 | 428,000,000 | 6,722,000,000 |
| Dec 2025 | 1,144,000,000 | 589,000,000 | 19,000,000 | -276,000,000 | 13,358,000,000 | 545,000,000 | 6,811,000,000 |
| Sep 2025 | 1,137,000,000 | 607,000,000 | 27,000,000 | -34,000,000 | 13,551,000,000 | 505,000,000 | 6,802,000,000 |
| Jun 2025 | 1,241,000,000 | 713,000,000 | 85,000,000 | 11,000,000 | 13,742,000,000 | 539,000,000 | 6,967,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$577,000,000
Investing CF
$-281,000,000
Financing CF
$-392,000,000
CapEx
$-262,000,000
Dividends Paid
—
Buybacks
$-47,000,000
EPS Diluted TTM
$-0.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,125,000,000
Inventory
$1,717,000,000
Receivables
$1,154,000,000
ST Investments
—
EBIT TTM
$40,000,000
Pretax Income TTM
$-197,000,000
Interest Exp TTM
$237,000,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,893,000,192
EBITDA
$970,000,000
Free Cash Flow
$692,124,992
Enterprise Value
$16,108,514,304
Total Cash
$428,000,000
Total Debt
$4,300,000,256
Shares Out
499,449,583
Trailing EPS
$-0.50
Book Value
$13.02
ROE
-3.8%
ROA
1.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,715,000,000 | 252,000,000 | -232,000,000 | 13,358,000,000 | 6,811,000,000 | — | 560,000,000 |
| Dec 2024 | 4,439,000,000 | 251,000,000 | 338,000,000 | 12,614,000,000 | 6,518,000,000 | — | 541,000,000 |
| Dec 2023 | 4,417,000,000 | 326,000,000 | -1,231,000,000 | 14,362,000,000 | 8,139,000,000 | — | 271,000,000 |
| Dec 2022 | 4,411,000,000 | 384,000,000 | -78,000,000 | 15,491,000,000 | 8,202,000,000 | — | 452,000,000 |
TTM Snapshot
Revenues TTM
$4,255,000,000
NetIncome TTM
$-901,000,000
OpCashFlow TTM
$0
Assets (Latest)
$12,614,000,000
Forward EPS
$1.19
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $23.00 · spot: $24.50 · call volume: 202 · put volume: 86Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IONS | IONIS PHARMACEUTICALS INC | $12.33B | $74.58 | — |
| AXSM | Axsome Therapeutics, Inc. | $12.64B | $245.64 | — |
| ASND | Ascendis Pharma A/S | $13.17B | $213.23 | — |
| BBIO | BridgeBio Pharma, Inc. | $13.26B | $67.68 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.19B | $57.91 | — |
News headlines (Yahoo Finance, 1h cache)
Is It Too Late To Consider Elanco Animal Health (ELAN) After Its Strong 1 Year Rally?
2026-06-05 06:07 · Yahoo
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
2026-06-04 21:30 · Yahoo
A Flesh-Eating Fly Adds to the Beef Industry’s List of Problems
2026-06-04 20:21 · Yahoo
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
2026-06-04 16:15 · Yahoo
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
2026-06-03 11:26 · Yahoo
A Look At Elanco (ELAN) Valuation After Early Befrena Launch And Renewed Investor Optimism
2026-06-01 21:14 · Yahoo
3 of Wall Street’s Favorite Stocks We Think Twice About
2026-06-01 19:20 · Yahoo
Elanco (ELAN) Is Up 9.8% After Launching Befrena, Its Second USDA-Approved Pet Biologic
2026-06-01 18:12 · Yahoo
3 Healthcare Stocks We Keep Off Our Radar
2026-05-28 16:30 · Yahoo
Monumental Public-Private Initiative Forms to Permanently Close America's Protein Gap
2026-05-27 16:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.